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39‑year‑old male presented for
the evaluation of decreased vision
and discomfort of the right eye. The
patient had an ocular history notable for
primary open‑angle glaucoma. Surgical
history included cataract extraction with
intraocular lens implantation at age 14.
Two years before presentation, lens
dislocation was noted, and the patient
underwent a scleral sutured intraocular
lens with a pars plana vitrectomy and pars
plana Ahmed glaucoma valve placement.
At the time of presentation, the patient
was using topical dorzolamide‑timolol
22.3/6.8 mg/mL twice daily, brimonidine
0.2% twice daily, latanoprost 0.005%
once daily, and netarsudil 0.02% once
daily.
Clinical evaluation revealed counting
fingers vision at four feet in the right eye.
Intraocular pressure was 22 mmHg and
central corneal thickness (CCT) as measured
by pachymetry was 768 µm. Slit‑lamp
examination was notable for diffuse limbus
to limbus bullous reticular epithelial
edema [Figure 1]. Anterior segment
optical coherence tomography (AS‑OCT)
was obtained showing the unique
pattern of localized bullous epithelial
edema [Figure 2].
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Differential diagnosis included intraocular
pressure‑related edema, corneal edema
due to corneal endothelial loss after
multiple intraocular surgeries, and
netarsudil‑associated corneal edema.
Netarsudil was discontinued with close
monitoring of intraocular pressure, and the
patient underwent cyclophotocoagulation
for intraocular pressure reduction.
After 4 months from initial evaluation,
best‑corrected visual acuity improved to
20/70 in the right eye with an intraocular
pressure of 12 mmHg. CCT decreased
to 598 µm. Examination demonstrated
the resolution of the reticular epithelial
edema [Figure 3], although trace stromal
edema was noted. AS‑OCT confirmed
the absence of reticular epithelial
edema [Figure 4].
Rho kinase (ROCK) inhibitors have gained
popularity in ophthalmology, especially
given their role in intraocular pressure
reduction. Netarsudil 0.02% is a topical ROCK
inhibitor marketed as Rhopressa (Aerie
Pharmaceuticals, Bedminster, NJ) and
was approved by the Food and Drug
Administration in 2017 as a once daily drop
for the reduction of intraocular pressure.[1]
Ocular adverse events occur in 73% of patients,
and the most commonly reported local side
effects include conjunctival hyperemia (50%),
subconjunctival hemorrhage (15%),
and nonvisually significant cornea
verticillata (9%).[2]
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Figure 2: Prominent bullous epithelial edema as visualized with anterior segment
optical coherence tomography

Figure 1: Slit‑lamp photo of the right eye on presentation demonstrating limbus to
limbus bullous reticular epithelial edema
Figure 4: Anterior segment optical coherence tomography demonstrating resolution
of the epithelial bullae after discontinuation of netarsudil

properly addressed with discontinuation of the topical
medication to allow for improvement without need for
surgical intervention.
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Figure 3: Slit‑lamp photo illustrating improvement of corneal edema after
discontinuation of netarsudil
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A unique side effect of netarsudil 0.02% is bullous
reticular epithelial edema, especially in patients with
previous corneal stromal edema.[3] Similar to previous
reports, this patient had mild stromal edema; this
was noted on clinical examination and evident from
a mildly thickened pachymetry at follow‑up. ROCK
inhibitors optimize endothelial cell proliferation and
adhesion.[4] This unique presentation of edema has
an unclear mechanism, with hypotheses including a
potential shift of stromal edema to the cornea epithelium
due to improved endothelial function with clearing of
the stroma posteriorly, as well as direct effects on corneal
epithelial intercellular junctions.[3]
This case illustrates the use of AS‑OCT in the evaluation
of the reticular pattern of bullous epithelial corneal
edema. After proper identification, this condition can be
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